NCT02243592 2026-03-18
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
National Cancer Institute (NCI)
Active not recruiting
Clinical Trials
3,972 trialsNCT02501174 2026-03-18
CONSOG
Centre Oscar Lambret
Completed
NCT03030378 2026-03-18
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04317105 2026-03-18
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05372614 2026-03-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-03-18
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05687110 2026-03-18
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-03-18
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06298357 2026-03-18
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
Phase 1 Completed
NCT06606990 2026-03-18
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
NCT07202507 2026-03-18
SNOOZE
Centre Oscar Lambret
Phase NA Recruiting
NCT07226180 2026-03-18
Development and Application of Patient-Derived Models of Cancer
Certis Oncology Solutions, Inc
Enrolling by invitation
NCT04585958 2026-03-17
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04958239 2026-03-17
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
NCT07201038 2026-03-17
UF-WGS
University of Cambridge
Recruiting
NCT07476443 2026-03-17
VitC-CoQ10
Ain Shams University
Phase 2/3 Not yet recruiting
NCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
NCT01415258 2026-03-16
VULNERABILITE
Centre Oscar Lambret
Completed
NCT02439047 2026-03-16
MESO-PATCH
Centre Oscar Lambret
Phase NA Terminated
NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05887882 2026-03-16
PNOC028
University of California, San Francisco
Phase 1 Recruiting
NCT06072833 2026-03-16
Characterizing and Addressing Financial Toxicity in AYAs With Cancer
Columbia University
Phase NA Completed
NCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT00580515 2026-03-13
Trial of Family Focused Grief Therapy in Palliative Care and Bereavement
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT04318886 2026-03-13
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Phase 3 Active not recruiting
NCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT05909202 2026-03-13
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06178614 2026-03-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06941272 2026-03-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07454031 2026-03-13
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
Phase 1 Not yet recruiting
NCT07471425 2026-03-13
TOLERATE
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
NCT07471958 2026-03-13
eREACH3
Abramson Cancer Center at Penn Medicine
Recruiting
NCT02908906 2026-03-12
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04442425 2026-03-12
Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
National Institutes of Health Clinical Center (CC)
Completed
NCT04803604 2026-03-12
CASCADE
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting